- Phase 3 HDV D-LIVR (Lonafarnib) to Complete Enrollment in 2021 - Phase 3 HDV LIMT-2 (Lambda) to Initiate in 2021 - Strong Cash Position with $176 Million Pro-Forma Cash to Begin 2021 PALO ALTO, Calif. , March 9, 2021 /PRNewswire/ -- Eiger BioPharmaceuticals, Inc.

- Primary and Secondary Endpoints Achieved with Statistical Significance - FDA and EMA Concurrence on Single Pivotal Trial Toward Registration PALO ALTO, Calif. , Feb. 23, 2021 /PRNewswire/ -- Eiger BioPharmaceuticals, Inc (Nasdaq: EIGR), a commercial-stage biopharmaceutical company focused on the

- Lambda has potential to improve clinical outcomes and curb community spread - Fewer emergency room visits with Lambda treatment compared to placebo PALO ALTO, Calif. , Feb. 8, 2021 /PRNewswire/ --  Eiger BioPharmaceuticals, Inc (Nasdaq:EIGR), a commercial-stage biopharmaceutical company focused